EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognosis and Toxicity Stratified by Best Tumor Burden Change in Japanese Patients With Advanced Melanoma Treated With First‐Line Programmed Cell Death Protein 1 Monotherapy

Ken Horisaki iD, Shusuke Yoshikawa iD, Wataru Omata, Arata Tsutsumida, Yoshio Kiyohara

The Journal of Dermatology · 2025

DOI: 10.1111/1346-8138.17938 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Ken Horisaki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan. Hauptthemen laut MEDLINE: Melanoma, Programmed Cell Death 1 Receptor, Immune Checkpoint Inhibitors, Skin Neoplasms. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in patients with advanced malignant melanoma (MM). However, more than half of patients receiving anti‐programmed cell death protein‐1 (PD‐1) antibody monotherapy still fail to respond, with response rates varying by race and melanoma subtype. Additionally, immune‐related adverse events (irAEs) remain a major concern. Although the best overall response based on Response Evaluation Criteria in Solid Tumors version 1.1 is commonly used in clinical trials to assess efficacy, its utility in predicting prognosis and toxicity in real‐world clinical settings remains unclear. This retrospective cohort study conducted at Shizuoka Cancer Center in Japan evaluated the association between best tumor burden change (BTBC) in target lesions and prognosis or toxicity among Japanese patients with stage IV MM who received PD‐1 monotherapy as first‐line treatment. A total of 115 patients were analyzed. Prognosis improved proportionally with reductions in tumor burden from baseline. No significant difference was observed in overall survival between the partial response group and the stable disease group ( p = 0.833). However, BTBC < 0% was a significant indicator of a favorable long‐term prognosis ( p < 0.001). The development of new lesions indicated poor prognosis; however, BTBC ≥ 0% represented poor prognosis regardless of new lesions. Regarding toxicity, the incidence of any‐grade irAEs was significantly higher in the BTBC < 0% group than in the BTBC ≥ 0% group ( p < 0.001), suggesting that greater tumor shrinkage correlated with increased toxicity. These findings indicate that BTBC may serve as a more accurate predictor of prognosis and toxicity than best overall response in clinical practice. Incorporating BTBC into treatment planning and toxicity monitoring could improve management of stage IV MM, though future prospective studies are needed to establish standardized BTBC criteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsSkin NeoplasmsHumansMaleFemaleRetrospective StudiesAgedMiddle AgedJapanPrognosisTumor BurdenAged, 80 and overAdultNeoplasm StagingTreatment OutcomeResponse Evaluation Criteria in Solid TumorsEast Asian People

Stichwörter der Autor:innen

immune‐check point inhibitormelanomanivolumabpembrolizumab

Substanzen

Programmed Cell Death 1 ReceptorImmune Checkpoint InhibitorsPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan.
  • Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

ORCID-Profile: Ken Horisaki, Shusuke Yoshikawa

Zitieren

APA

Horisaki, K., Yoshikawa, S., Omata, W., Tsutsumida, A., & Kiyohara, Y. (2025). Prognosis and Toxicity Stratified by Best Tumor Burden Change in Japanese Patients With Advanced Melanoma Treated With First‐Line Programmed Cell Death Protein 1 Monotherapy. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17938

Vancouver

Horisaki K, Yoshikawa S, Omata W, Tsutsumida A, Kiyohara Y. Prognosis and Toxicity Stratified by Best Tumor Burden Change in Japanese Patients With Advanced Melanoma Treated With First‐Line Programmed Cell Death Protein 1 Monotherapy. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17938

BibTeX
@article{Horisaki2025,
  author = {Horisaki, Ken and Yoshikawa, Shusuke and Omata, Wataru and Tsutsumida, Arata and Kiyohara, Yoshio},
  title = {Prognosis and Toxicity Stratified by Best Tumor Burden Change in Japanese Patients With Advanced Melanoma Treated With First‐Line Programmed Cell Death Protein 1 Monotherapy},
  journal = {The Journal of Dermatology},
  year = {2025},
  doi = {10.1111/1346-8138.17938}
}
Kostenlos starten →